

Supplementary Online Content

Bae JM, Jung HM, Hong BY, et al. Phototherapy for vitiligo: a systematic review and meta-analysis. *JAMA Dermatol*. Published online March 29, 2017.
doi:10.1001/jamadermatol.2017.0002

eTable 1. Predetermined Search Terms in Each Database

eTable 2. Interventions and Clinical Outcomes of Phototherapy for Vitiligo

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Predetermined Search Terms in Each Database

Database	Search terms
Pubmed	vitiligo[title] AND (phototherapy OR psoralen OR PUVA OR ultraviolet OR NBUVB OR narrow band) AND (randomized controlled trial[PT] OR controlled clinical trial[PT] OR randomized[TIAB] OR randomised[TIAB] OR placebo[TIAB] OR randomly[TIAB] OR trial[TIAB] OR controlled[TIAB] OR comparative[TIAB] OR prospective[TIAB])
Embase	vitiligo:ti AND ('phototherapy'/exp OR phototherapy OR 'psoralen'/exp OR psoralen OR 'puva'/exp OR puva OR 'ultraviolet'/exp OR ultraviolet OR nbuvb OR 'NBUVB' OR 'narrow band') AND (randomized AND controlled AND trial OR controlled AND clinical AND trial OR randomized:ab,ti OR randomised:ab,ti OR placebo:ab,ti OR randomly:ab,ti OR trial:ab,ti OR controlled:ab,ti OR comparative:ab,ti OR prospective:ab,ti)
Cochrane library	vitiligo AND (phototherapy OR psoralen OR PUVA OR ultraviolet OR NBUVB OR narrow band)

eTable 2. Interventions and Clinical Outcomes of Phototherapy for Vitiligo

Study	Country	Initial dose (mJ/cm ²)	Frequency (weekly)	Treatment duration	Enrolled patients	Completed patients	Degree of repigmentation			Comments
							≥75%	≥50%	≥25%	
A. NB-UVB										
Westerhof and Nieuweboer-Krobotova, ⁸ 1997	The Netherlands	75	Twice	12 months	51	51	32	ND	50	
Njoo et al, ⁹ 2000	The Netherlands	250	Twice	12 months	51	51	27	ND	42	
Al Rubaie, ¹⁰ 2002	UAE	ND	ND	6-12 months	13	13	ND	8	10	
Park et al, ¹¹ 2003	Korea	250	Twice	>6 months	13	13	7	8	11	
Hamzavi et al, ¹² 2004	Canada	70% of MED	Thrice	6 months	22	22	4	9	14	
Brazzelli et al, ¹³ 2005	Italy	180-200	Thrice	6 months	10	10	5	ND	8	
Kanwar and Dogra, ¹⁴ 2005	India	280	Thrice	Up to 12 months	26	26	15	19	ND	
Kanwar et al, ¹⁵ 2005	India	280	Thrice	12 months	15	12	8	10	ND	Results exclusive of 2 overlapped patients in ref. 13
Anbar et al, ¹⁶ 2005	The Netherlands	280	Twice	>6 months	135	97	47	ND	73	
Arca et al, ¹⁷ 2006	Turkey	100	Thrice	10 weeks	24	24	ND	10	19	
Goktas et al, ¹⁸ 2006	Turkey	140	Thrice	6 months	28	28	0	6	17	
Bhatnagar et al, ¹⁹ 2007	India	280	Thrice	12 months	25	25	4	13	24	
Dell'Anna et al, ²⁰ 2007	The Netherlands	70% of MED	Twice	6 months	14	11	2	4	ND	
Nicolaidou et al, ²¹ 2007	Greece	200-300	Twice	12 months	84	70	ND	ND	ND	Reported outcome according to body site only

<i>Table continued</i>										
Sitek et al, ²² 2007	Norway	200	Thrice	Up to 12 months	34	31	11	ND	19	
Yones et al, ²³ 2007	England	100	Twice	6 months	25	25	8	16	9	
Percivalle et al, ²⁴ 2008	Italy	330	Twice	Up to 12 months	53	53	2	19	36	
Elgoweini and Nour El Din, ²⁵ 2009	Egypt	210	Thrice	6 months	12	9	3	5	7	
Esfandiarpour et al, ²⁶ 2009	Iran	280	Thrice	3 months	25	25	ND	ND	ND	Reported outcome according to body site only
Kishan Kumar et al, ²⁷ 2009	India	250	Twice	Up to 12 months	150	150	26	ND	99	
Stinco et al, ²⁸ 2009	Italy	280	Thrice	6 months	13	13	ND	ND	ND	Reported outcome according to body site only
Yuksel et al, ²⁹ 2009	Turkey	140	Thrice	6 months	15	15	0	2	10	
Nordal et al, ³⁰ 2011	Norway	ND	Twice/thrice	3 months	46	40	9	11	24	
Sapam et al, ³¹ 2012	Nepal	280	ND	6 months	28	27	0	8	23	
Bansal et al, ³² 2013	India	330	Thrice	5 months	ND	20	ND	ND	ND	Reported outcome according to body site only
El-Mofty et al, ³³ 2013	Egypt	500	Thrice	4 months	20	19	3	ND	ND	
Satyanarayan et al, ³⁴ 2013	India	ND	Thrice	6 months	2	21	6	11	19	
Baldo et al, ³⁵ 2014	Italy	ND	Twice	36 weeks	48	48	ND	ND	ND	Reported outcome according to body site only
Khullar et al, ³⁶ 2014	India	280	Thrice	24 weeks	27	25	6	11	20	

<i>Table continued</i>										
B. PUVA										
Al-Aboosi et al, ³⁷ 1995	Iraq	500	Twice	6-18 months	29	18	4	12	17	Trimethylpsoralen 0.6 mg/kg
Cestari et al, ³⁸ 2000 (A)	Brazil	43	Twice	3 months	14	9	ND	0	3	Topical 2% 4-dimethoxyamoidina
Cestari et al, ³⁸ 2000 (B)	Brazil	43	Twice	3 months	13	10	ND	3	4	Topical 8-MOP
Ermis et al, ³⁹ 2001	Turkey	MED	Twice	3 months	35	27	4	ND	ND	8-MOP, 0.5-0.6mg/kg
<i>Table continued</i>										
Cherif et al, ⁴⁰ 2003	Tunisia	500	Thrice	15 weeks	23	23	ND	7	16	8-MOP, 0.6mg/kg
Valkova et al, ⁴¹ 2004	Bulgaria	1000-1500	Thrice	4 months	17	17	ND	9	ND	8-MOP, 0.4mg/kg
Bhatnagar et al, ¹⁹ 2007	India	2000	Thrice	12 months	25	25	2	8	24	Trimethylpsoralen 0.6mg/kg
Yones et al, ²³ 2007	England	500	Twice	6 months	25	25	5	9	12	8-MOP, 25mg/m ²
Sapam et al, ³¹ 2012	Nepal	500-2500	ND	6 months	28	26	0	3	23	8-MOP, 0.6mg/kg
Singh et al, ⁴² 2013	India	2000	Thrice	36 weeks	18	12	5	5	5	8-MOP, 0.6mg/kg

Abbreviations: MED, minimal erythema dose; MOP, methoxy-psoralen; ND, not determined;